Market Research Reports

Biosimilars Market - Global And China Forecast, Share, Size, Growth And Industry Analysis (2010 - 2017)

 

Description


The research report on the biosimilars (follow-on biologics) market is a valuable resource for entities operating within and on the periphery of this market. This comprehensive market study reviews the global market to provide an estimate of the global market size. It also provides market figures and CAGR for each segment within the biosimilars market. The overall market growth rate is analyzed with respect to existing and anticipated market trends. Our team of seasoned analysts not only provides an overview of the current advancements in the industry but also discusses their impact on biosimilars market of the future.

The report studies current trends and the future bargaining power of various stakeholders using Porter’s five forces analysis. The Company Profiles section contains profiles of leading industry names, and their growth strategies for the future. Additionally, macro and micro factors that directly influence the growth and sustenance of established and prospective market players are reviewed in the market research report. This report is a result of extensive primary and secondary research efforts geared towards obtaining accurate forecasts of the biosimilars market.

Overview 

Biosimilars are also commonly referred to as follow-on biologics. These are essentially copies of biopharmaceuticals (biological drugs) that provide cost savings, making them a preferred choice. Users and the medical fraternity alike stand to benefit from the lower costs of these drugs. However, biosimilars have also been at the center of raging debates about whether they violate the interest of the original developers of biopharmaceutical products. Questions have been raised about whether such copied drugs are stable and safe. These worldwide concerns have, to some degree, negatively impacted the biosimilars market. 

On the other hand, this market immensely benefits from the low entry barriers that exist in developing economies. In these regions, there are no clear regulatory norms that govern the approval of such follow-on biologics. Most players try to off-set the hurdles experienced from non-approvals in the U.S. market by making inroads into emerging markets such as South East Asia. 

Growth propellants in the biosimilars market are: the growing cost of healthcare, expensive medication and drugs, a rapid increase in the number of aged people worldwide. However, these advantages are at times overshadowed by doubts about risks associated with biosimilars. The risks for drug developers are high as well – especially in the event of a drug failing during the development stages. 

Overall, however, market analysts anticipate an encouraging growth potential for the biologics market between 2013 and 2019. Companies that assemble a cross-disciplinary talent pool and target global expertise in biological solutions while keeping a watch on the regulatory environment can ensure success in the long run

Companies mentioned

A few leading entities that find mention in this report are: Astra Zeneca, Abbott, Bristol-Myers Squibb, Cipla, Genentech, Ranbaxy Laboratories, and others.

Major geographies analyzed under this research report are: 
  • Europe
  • North America 
  • Asia-Pacific 
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements in the micro servers industry
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments

Table of Contents


TABLE OF CONTENTS

1) INTRODUCTION
 1.1 Objective of the Research
 1.2 Report Highlights
 1.3 Scope of the Report
 1.4 Research Methodology

2) MARKET OUTLINE
2.1. Defining the global biosimilar market
2.2. Driving factor analysis
2.2.1. Demand and Supply-side drivers
2.2.2. Restraints & opportunities
2.2.3. Key points
2.3. Issues related with biosimilar
2.4. Potential matrix for global biosimilar 
2.4.1. Products
2.4.2. Applications
2.5. Biosimilar market dynamics
2.6. Pricing of biosimilar drug
2.7. Biosimilar products geographical trend

3) BIOSIMILAR PRODUCTS MARKET
3.1. Recombinant glycosylated proteins
3.1.1. Drivers & restraints
3.1.2. Erythropoietin (EPO)
3.1.3. Urokinase
3.1.4. Glucocerebrosidase
3.1.5. Monoclonal antibodies
3.1.5.1. Chimaeric antibodies
3.1.5.2. Humanized / cdr-grafted / reshaped antibodies
3.1.5.3. Human antibodies and fusion protein
3.1.6. Follitropin
3.1.7. Thyrotropin
3.1.8. Becaplermin
3.1.9. Granulocyte-macrophage-CSF (GM-CSF)
3.1.10. Recombinant Human DNASE (RHDNASE)
3.1.11. Factor VIIA
3.1.11.1. Factor VIII
3.1.11.2. Factor IX
3.1.12. Activated protein-c
3.1.13. Tissue plasminogen activator
3.2. Recombinant non-glycosylated protein
3.2.1. Drivers and restraints
3.2.2. Insulin
3.2.2.1. Drivers & restraints
3.2.2.2. Opportunities
3.2.3. Interferons
3.2.3.1. Interferon alfa
3.2.3.2. Interferon beta-1a
3.2.3.3. Interferon gamma
3.2.4. Recombinant human growth hormone
3.2.5. Lepirudin
3.2.6. Interleukin-11
3.2.7. Anakinra
3.2.8. Interleukin – 2 (Il-2)
3.2.9. Granulocyte colony-stimulating factor (G-CSF)
3.3. Peptides
3.3.1. Drivers
3.3.2. Restraints & opportunities
3.3.3. Cyclosporine
3.3.4. Calcitonin
3.3.5. Bivalirudin
3.3.6. Enfuvirtide
3.3.7. Glucagon
3.3.8. Eptifibatide
3.3.9. Octreotide
3.3.10. Desmopressin
3.3.11. LH-RH (Leuprolide)
3.3.12. Nesiritide
3.3.13. Teriparatide

4) BIOSIMILAR TECHNOLOGY
4.1. Recombinant DNA technology (RDNA technology)
4.1.1. Drivers
4.1.2. Restraints & opportunities
4.2. Chromatography
4.2.1. Drivers & opportunities
4.2.2. Top player analysis
4.2.3. Liquid chromatography (LC)
4.2.4. Gas chromatography (GC)
4.3. Bioassay
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Techniques in bioassay
4.3.3.1. Six point assay
4.3.3.2. Multiple point assays
4.3.3.3. Interpolation method
4.3.3.4. Bracketing method
4.3.3.5. Matching bioassays
4.4. Monoclonal antibodies (MAB) technology
4.4.1. Drivers
4.4.2. Restraints & opportunities
4.4.3. Top player analysis
4.5. Western blotting
4.5.1. Drivers
4.5.2. Restraints & opportunities
4.6. Protein sequencing
4.6.1. Drivers
4.6.2. Restraints & opportunities
4.7. Nuclear magnetic resonance (NMR) technology
4.7.1. Drivers
4.7.2. Restraints & opportunities
4.8. Electrophoresis
4.8.1. Drivers
4.8.2. Restraints & opportunities
4.8.3. GEL electrophoresis
4.8.4. Capillary electrophoresis
4.9. Mass spectrometry
4.9.1. Drivers
4.9.2. Restraints

5) BIOSIMILAR APPLICATION MARKET
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.2. Oncology
5.2.1. Drivers
5.2.2. Restraints & opportunities
5.2.3. Lung cancer
5.2.4. Colorectal cancer
5.2.5. Breast cancer
5.2.6. Cervical cancer
5.2.7. Leukemia
5.2.7.1. Drivers
5.2.8. Prostate cancer
5.3. Infectious diseases
5.3.1. HIV/Aids
5.3.1.1. Drivers
5.3.2. Hepatitis B
5.3.3. Hepatitis C
5.4. Chronic and autoimmune diseases
5.4.1. Diabetes
5.4.1.1. Drivers
5.4.2. Neutropenia
5.4.3. Multiple sclerosis
5.4.3.1. Drivers
5.4.3.2. Inhibitors and opportunities
5.4.4. Cystic fibrosis
5.4.5. Rheumatoid arthritis (RA)
5.4.5.1. Drivers
5.4.5.2. Restraints
5.4.6. Acromegaly
5.4.6.1. Driver
5.4.7. Leprosy
5.5. Hematology
5.5.1. Drivers
5.5.2. Chemotherapy induced anemia
5.5.2.1. Drivers
5.5.2.2. Restraints and opportunities
5.5.3. Hemophilia
5.5.4. Pulmonary embolism
5.5.4.1. Drivers
5.6. Growth hormone deficiency (GHD)
5.6.1. Drivers
5.7. Other diseases
5.7.1. Gaucher disease
5.7.2. Osteoporosis
5.7.3. Fertility disorders (Infertility)
5.7.4. Skin ulcer
5.7.5. Hypoglycemia
5.7.6. Nocturnal enuresis
5.7.7. Congestive heart failure (CHF)
5.7.8. Systemic sepsis
5.7.9. Others

6) BIOSIMILAR SERVICE MARKET
6.1. Clinical trials
6.1.1. Drivers & restraints
6.1.2. Phase I
6.1.3. Phase II
6.1.4. Phase III
6.2. Contract research and manufacturing services
6.2.1. Drivers
6.2.2. Restraints & opportunities

7) GEOGRAPHIC ANALYSIS
7.1. North America biosimilar market
7.2. EMEA biosimilar market
7.3. Asia-Pacific biosimilar market
7.4. Latin America Biosimilars market

8) COMPANY PROFILES
8.1.1. Teva
8.1.2. Sandoz
8.1.3. Hospira
8.1.4. Mylan
8.1.5. Actavis
8.1.6. Biocon Ltd.
8.1.7. Cipla Ltd.
8.1.8. Dr. Reddy's Laboratories Ltd.
8.1.9. Wockhardt Ltd
8.1.10. Stada Arzneimittel AG

Enquiry Before Buying


 
Pre Book Price: $4315.5 Original Price: $4795
Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research